| Line Item | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
|---|---|---|---|---|---|
| Continuing operations | |||||
| Research and development costs | |||||
| Exploration and evaluation expenses | |||||
| Corporate and administrative expenses | |||||
| Business development expenses | |||||
| Share-based payment expenses | |||||
| Finance income | |||||
| Finance costs | |||||
| Other income and expenses | |||||
| Loss before income tax | |||||
| Income tax expense | |||||
| Loss for the year | |||||
| Loss attributable to shareholders of IperionX Limited | |||||
| Items that may be reclassified subsequently to profit or loss: | |||||
| Exchange differences arising on translation into presentation currency | |||||
| Other comprehensive income (loss) for the year, net of tax | |||||
| Total comprehensive loss for the year | |||||
| Total comprehensive loss attributable to shareholders of IperionX Limited | |||||
| Basic loss per share (US$ per share) | |||||
| Diluted loss per share (US$ per share) |